Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (18 March 2018)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month.

Australian applications

Here are the 157 PCT patent applications relevant to Australia's Life Sciences sector that published in 2013, for a publication rate of 3.0 applications per week:​
  • WO/2013/188918, Improved recombinant viruses, Australian National University, 27 December 2013
  • WO/2013/188928, Dosage regime for animal treatment, Smartvet Pty Ltd, 27 December 2013
  • WO/2013/192566, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma, 27 December 2013
  • WO/2013/188926, Method and composition for delivering a compound through a biological barrier, University of Queensland, 27 December 2013
  • WO/2013/185177, Influenza vaccine, CSL Ltd, 19 December 2013
  • WO/2013/185178, Nanoemulsions, University of Queensland, 19 December 2013
  • WO/2013/185165, CD-52 antibodies and their use in determining and enhancing an immune response in a subject, Walter and Eliza Hall Institute of Medical Research, 19 December 2013
  • WO/2013/185181, Diagnostic method for diseases characterised by Ro/La autoimmunity, Central Adelaide Local Health Network and Flinders University, 19 December 2013
  • WO/2013/181696, Vaccination with interleukin-4 antagonists, Australian National University, 12 December 2013
  • WO/2013/181691, A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor, Macfarlane Burnet Institute for Medical Research and Public Health, 12 December 2013
  • WO/2013/181697, Bicyclo[6.1.0]non-4-yne compounds suitable for use as linkers in biological applications, University of Melbourne, 12 December 2013
  • WO/2013/181694, Compositions and methods for treating Crohn's disease and related conditions and infections, Gaurav Agrawal, 12 December 2013
  • WO/2013/177608, Method of treating Scedosporium spp. infection, Biodiem, 5 December 2013
  • WO/2013/177607, Methods and compositions for improving a response to a metabolic stress, Hit Southern Pty Ltd, 5 December 2013
  • WO/2013/177633, Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia, Bionomics, 5 December 2013
  • WO/2013/177605, Destructured and modified virus immunogens, Monash University, 5 December 2013
  • WO/2013/173874, Composition and method for management of diabetes or pre-diabetes, Omniblend Innovation Pty Ltd, 28 November 2013
  • WO/2013/173858, A method of weight reduction, Verva Pharmaceuticals Ltd, 28 November 2013
  • WO/2013/173859, A method of improving liver function, Verva Pharmaceuticals Ltd, 28 November 2013
  • WO/2013/173881, A dermatological compositions, Andrew Tuan-Anh Le , 28 November 2013
  • WO/2013/173862, Improved synthesis, Oncology Research International Limited, 28 November 2013
  • WO/2013/170315, A method of treatment and agents useful for same, Paranta Biosciences Ltd, 21 November 2013
  • WO/2013/170305, Cellular vaccine and method of inducing an immune response in a subject, University of Adelaide, 21 November 2013
  • WO/2013/170317, Liquid formulation, Luoda Pharma Pty Ltd, 21 November 2013
  • WO/2013/173129, Treatment of AMD using AAV sFlt-1, Avalanche Australia Pty Ltd and Lions Eye Institute, 21 November 2013
  • WO/2013/167635, Therapeutic use of indole-dihydro-imidazole derivatives, Noscira, S.A. and University of Queensland , 14 November 2013
  • WO/2013/166545, 6-oxopurine phosphoribosyltransferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry, 14 November 2013
  • WO/2013/166555, Methods of treating cancer using angiogenin or an angiogenin agonist, Murray Goulburn Co-Operative Co., 14 November 2013
  • WO/2013/166557, Methods for treating cachexia, Murray Goulburn Co-Operative Co., 14 November 2013
  • WO/2013/163689, Vaccine and uses thereof, University of Sydney, Sydney Children's Hospital Network, Royal Prince Alfred Hospital , 7 November 2013
  • WO/2013/163675, Substituted 3-haloallylamine inhibitors of SSAO and uses thereof, Pharmaxis, 7 November 2013
  • WO/2013/159151, Combination meloxicam and xylazine therapy in animals, Troy Laboratories Pty Ltd, 31 October 2013
  • WO/2013/159140, EDS005 skin cancer cream, Brenden Edser and Jason Edser, 31 October 2013
  • WO/2013/159155, Oncolytic Clostridium ghonii strains, and methods of production and use, Griffith University, 31 October 2013
  • WO/2013/155555, Peptides for the binding of nucleotide targets, University of Western Australia and University of Oregon, 24 October 2013
  • WO/2013/156954, Stem cell preparations and methods of use, Medela Holding AG, 24 October 2013
  • WO/2013/152392, Viral polymerase inhibitors, Biota, 17 October 2013
  • WO/2013/152391, Viral polymerase inhibitors, Biota, 17 October 2013
  • WO/2013/153451, Controlled release formulations of opioids, QRxPharma, 17 October 2013
  • WO/2013/149306, Antibodies to HtrA3, Prince Henry's Institute of Medical Research, 10 October 2013
  • WO/2013/150382, Herbal compositions for the prevention or treatment of benign prostatic hyperplasia and related disorders, Tracey Seipel, 10 October 2013
  • WO/2013/150292, Composition for the treatment of inflammatory and immune disorders, Eaglepharma Pty Ltd and Andrew Bridle, 10 October 2013
  • WO/2013/142901, Silk polypeptides, Commonwealth Scientific and Industrial Research Organisation, 3 October 2013
  • WO/2013/142912, Methods and compositions for reducing ocular discomfort, Brien Holden Vision Institute, 3 October 2013
  • WO/2013/138871, Immunomodulatory agent and uses therefor, University of Queensland, 26 September 2013
  • WO/2013/138863, Kinase inhibitors for the treatment of cancer, University of New South Wales, 26 September 2013
  • WO/2013/138860, Antibacterial compounds, Biota, 26 September 2013
  • WO/2013/138864, Tissue scaffold, Neopec Pty Ltd, 26 September 2013
  • WO/2013/137854, Antibodies that bind to nanoparticles, Empire Technology Development, 19 September 2013
  • WO/2013/134822, Method for treating inflammation, James Cook University, 19 September 2013
  • WO/2013/134819, Cosmetic composition, Climax Holdings Pty Ltd, 19 September 2013
  • WO/2013/131124, Dietary supplement for pet mammals, Gratuk Technologies Pty Ltd, 12 September 2013
  • WO/2013/131125, Dietary supplement, Gratuk Technologies Pty Ltd, 12 September 2013
  • WO/2013/131143, Micrornas and uses thereof, University of Western Australia, 12 September 2013
  • WO/2013/126962, Therapeutic and diagnostic agents, University of Sydney, 6 September 2013
  • WO/2013/126963, Pain treatment, Benitec Biopharma, 6 September 2013
  • WO/2013/116903, Methods for the characterisation of interaction sites on target proteins, Phylogica  and Cambridge Enterprise Ltd, 15 August 2013
  • WO/2013/113060, Peptide, University of Western Australia, 8 August 2013
  • WO/2013/113067, Improvements in tear film stability, University of Sydney and University of New South Wales, 8 August 2013
  • WO/2013/113074, Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor, Antisense Therapeutics, 8 August 2013
  • WO/2013/113071, Branched polymers, Commonwealth Scientific and Industrial Research Organisation, 8 August 2013
  • WO/2013/113774, Factor XII inhibitors for the treatment of neurological inflammatory disorders, CSL Ltd, Julius-Maximilians-Universitaet-Wuerzburg and Westfaelische Wilhelms-Universitaet Muenster , 8 August 2013
  • WO/2013/110134, Heterocyclic compounds and methods for their use, Spinifex Pharmaceuticals Pty Ltd, 1 August 2013
  • WO/2013/110135, Heterocyclic compounds and methods for their use, Spinifex Pharmaceuticals Pty Ltd, 1 August 2013
  • WO/2013/110120, Peptide agents for cancer therapy, Inter-K Pty Ltd, 1 August 2013
  • WO/2013/110121, Assay for a biomarker of a central nervous system disorder, University of Sydney, 1 August 2013
  • WO/2013/102234, Formulation and method for treatment of pain and/or inflammation associated with a skin condition, UBS Ultimate Relief Pty Ltd, 11 July 2013
  • WO/2013/102242, Heterocyclic compounds and methods for their use, Spinifex Pharmaceuticals Pty Ltd, 11 July 2013
  • WO/2013/096878, Garcinia buchananii baker compounds, compositions and related methods, University of Idaho, University of Vermont, University of Adelaide and Technical University Munich, 27 June 2013
  • WO/2013/090978, Dosage regime for apolipoprotein formulations, CSL Ltd, 27 June 2013
  • WO/2013/091004, Prevention and treatment of Mycobacterium infection, University of Sydney and Centenary Institute of Cancer Medicine and Cell Biology , 27 June 2013
  • WO/2013/091001, A peptide-hydrogel composite, University of Sydney, 27 June 2013
  • WO/2013/091011, Heterocyclic urea compounds, Biota, 27 June 2013
  • WO/2013/091014, Antimicrobial agents, James Cook University and University of New South Wales, 27 June 2013
  • WO/2013/090991, TGF-beta therapy, University of Sydney, 27 June 2013
  • WO/2013/090989, Method of treating inflammatory bowel disease, CSL Ltd, 27 June 2013
  • WO/2013/090986, Treatment of seborrhoea, Mcfarlane Marketing (Aust.) Pty. Ltd., 27 June 2013
  • WO/2013/091006, Process for dry powder blending, Monash University, 27 June 2013
  • WO/2013/091008, Method of treating reduced ceruloplasmin functionality in the Central Nervous System, Mental Health Research Institute of Victoria, 27 June 2013
  • WO/2013/091020, Ophthalmic formulation, University of Western Sydney, 27 June 2013
  • WO/2013/086582, Genetic polymorphism and responsiveness to vitamin therapy of migraine, Griffith University, 20 June 2013
  • WO/2013/086574, Method of treatment, Central Adelaide Local Health Network and Flinders University, 20 June 2013
  • WO/2013/088250, Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors, EnGeneIC, 20 June 2013
  • WO/2013/085904, Oral spray formulations and methods for administration of sildenafil, Suda Pharmaceuticals, 13 June 2013
  • WO/2013/082656, Cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
  • WO/2013/082667, Use of growth hormone fragments, Metabolic Pharmaceuticals, 13 June 2013
  • WO/2013/082655, Functionalisation of cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
  • WO/2013/078500, Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug, Jurox Pty Ltd, 6 June 2013
  • WO/2013/078517, Methods for isolating constituents from nacre-coated shell or pearl, University of Western Australia, 6 June 2013
  • WO/2013/078511, Anti-NPY and PYY antibodies and uses thereof, Garvan Institute of Medical Research, 6 June 2013
  • WO/2013/078395, L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders, Institute for Ethnomedicine, 30 May 2013
  • WO/2013/075172, Improved synergistic anti-diabetic compositions, Ozstar Therapeutics Pty Ltd, 30 May 2013
  • WO/2013/075176, Compositions and methods for modulating uterine contractions, University of Newcastle, 30 May 2013
  • WO/2013/071356, Collagen-like silk genes, Commonwealth Scientific and Industrial Research Organisation, 23 May 2013
  • WO/2013/071365, A method of treatment and prophylaxis and compositions useful therefor, Macquarie University, 23 May 2013
  • WO/2013/071353, Apricitabine and PI combination therapy, Avexa, 23 May 2013
  • WO/2013/071374, Organic particulates having an emollient of oils, Ronald Greenberg, 23 May 2013
  • WO/2013/071355, Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 23 May 2013
  • WO/2013/072766, Process for cabazitaxel and intermediates thereof, Scinopharm Taiwan Ltd, 23 May 2013
  • WO/2013/073968, Agents for modulation of cell signalling, Industrial Research Ltd and Meat & Livestock Australia, 23 May 2013
  • WO/2013/067581, Cancer treatment, Children's Cancer Institute Australia for Medical Research, 16 May 2013
  • WO/2013/067591, Topical formulations for pain management, Relevare Australia Pty Ltd, 16 May 2013
  • WO/2013/067579, Adiposity-modulating molecules and uses therefor, University of Queensland, 16 May 2013
  • WO/2013/067578, Modulators of c3a receptors, University of Queensland, 16 May 2013
  • WO/2013/067597, Immunomodulatory conjugates, Ascend Biopharmaceuticals Pty Ltd, 16 May 2013
  • WO/2013/064909, Crystalline and non-crystalline forms of SGLT2 inhibitors, Scinopharm Taiwan Ltd, 10 June 2013
  • WO/2013/059879, Compositions and methods for the treatment of fibrosis and fibrotic diseases, Howard Florey Institute of Experimental Physiology and Medicine and Murdoch Children's Research Institute , 2 May 2013
  • WO/2013/059886, PAT-LM1 epitopes and methods for using same, Patrys, 2 May 2013
  • WO/2013/059881, Electrolyte purgatives, Thomas Borody, Sanjay Ramrakha, John Saxon and Antony Wettstein , 2 May 2013
  • WO/2013/059876, A method of treating mucus hypersecretion, Paranta Biosciences Ltd, 2 May 2013
  • WO/2013/059885, Polypeptide constructs and uses thereof, Teva Pharmaceuticals Australia Pty Ltd, 2 May 2013
  • WO/2013/056309, Novel plant defensins and use in the treatment of proliferative diseases, Hexima Ltd and Balmoral Australia Pty Ltd , 25 April 2013
  • WO/2013/057219, Method for improving the stability of purified Factor VIII after reconstitution, CSL Ltd, 25 April 2013
  • WO/2013/056298, Pharmaceutical compositions of resveratrol, Nad Life Pty Ltd, 25 April 2013
  • WO/2013/056304, Influenza immunotherapy, CSL Ltd, 25 April 2013
  • WO/2013/056308, Novel forms of plant defensins, Balmoral Australia Pty Ltd, 25 April 2013
  • WO/2013/053021, Antibodies to CD1D, Cephalon Australia Pty Ltd, 18 April 2013
  • WO/2013/053015, Meloxicam based formulations for providing analgesia in sheep, Troy Laboratories Pty Ltd, 18 April 2013
  • WO/2013/053008, Molecules which bind Clec9a, Walter and Eliza Hall Institute of Medical Research, 18 April 2013
  • WO/2013/050508, Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors, Cellzome Ltd, 11 April 2013
  • WO/2013/044298, Antibodies against TL1A and uses thereof, Cephalon Australia Pty Ltd, 4 April 2013
  • WO/2013/044314, In vivo synthesis of elastic fiber, University of Sydney, 4 April 2013
  • WO/2013/040647, Novel antimicrobial compounds, University of Adelaide and Monash University , 28 March 2013
  • WO/2013/040649, Therapeutics using adipose cells and cell secretions, Cell Ideas Pty Ltd, 28 March 2013
  • WO/2013/040648, Pneumococcal GlpO immunogen, University of Adelaide and Monash University , 28 March 2013
  • WO/2013/036994, Compounds for the treatment of HCV, Biota, 21 March 2013
  • WO/2013/036998, Treatment of bone diseases, Nepean Blue Mountains Local Health District, 21 March 2013
  • WO/2013/038259, Benzothiazinone derivatives as anti-tuberculosis agents, University of Queensland, 21 March 2013
  • WO/2013/033777, Methods for increasing osteoblastic function, Mesoblast, 14 March 2013
  • WO/2013/030568, Caninised tumour necrosis factor antibodies and methods of using the same, NVIP Pty Ltd, 7 March 2013
  • WO/2013/029116, Method for predicting treatment responsiveness, Monash University, 7 March 2013
  • WO/2013/026099, Fn14 binding proteins and uses thereof, Transbio Ltd, 28 February 2013
  • WO/2013/026089, Peptides for use in the treatment of Il-1 related diseases and conditions, C4M Pharmaceuticals Pty Ltd, 28 February 2013
  • WO/2013/023251, Soluble polypeptides, Affinity Biosciences Pty Ltd, 21 February 2013
  • WO/2013/023250, Controlled-release formulation, Baker IDI Heart & Diabetes Institute, 21 February 2013
  • WO/2013/024311, Amidoxime derivatives for the prevention and/or treatment of muscle atrophy, Pharma-Gene SA, 21 February 2013
  • WO/2013/020184, Flavonoid compounds, and methods of use thereof, Neuprotect Pty Ltd, 14 February 2013
  • WO/2013/020164, Compounds for treating Respiratory Syncytial Virus infections, Biota, 14 February 2013
  • WO/2013/020182, Antioxidant topical compositions, Stiefel Research Australia Pty Ltd, 14 February 2013
  • WO/2013/020183, Immunogenic compositions and methods therefor, University of Queensland, 14 February 2013
  • WO/2013/016754, Method and formulation for inhalation, Monash University, 7 February 2013
  • WO/2013/013275, Alkaline compositions and their dental and medical use, B Athanassiadis Dental Pty Ltd and LJ Walsh Dental Pty Ltd , 31 January 2013
  • WO/2013/014038, 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as PARP-1 inhibitors, Nerviano Medical Sciences S.R.L., 31 January 2013
  • WO/2013/013273, Modulators of protease activated receptors, University of Queensland, 31 January 2013
  • WO/2013/015674, Collagen nanostructures, Holista Biotech Sdn Bhd and Jamia Hamdard , 31 January 2013
  • WO/2013/011021, Use of c-FMS antagonists, University of Melbourne and Morphosys, 24 January 2013
  • WO/2013/010225, Enzymes for degrading organophosphates, Commonwealth Scientific and Industrial Research Organisation, 24 January 2013
  • WO/2013/010210, Oral compositions comprising an antacid, an anaesthetic and an inorganic matrix comprising silicon dioxide and titanium dioxide, Eupharma Pty Ltd, 24 January 2013
  • WO/2013/010218, Inhibition of clathrin, Freie Universität Berlin, University of Newcastle and Children's Medical Research Institute, 24 January 2013
  • WO/2013/007698, Pharmaceutical composition for neurological disorders, Gosforth Centre (Holdings) Pty Ltd, 17 January 2013
  • WO/2013/006906, Dermatan sulphate, pharmaceutical compositions and process for producing same, Commonwealth Scientific and Industrial Research Organisation, 17 January 2013
  • WO/2013/003912, Cryptate compounds, Australian Nuclear Science and Technology Organisation, 10 January 2013
  • WO/2013/003887, Nucleic acid complex, Commonwealth Scientific and Industrial Research Organisation, 10 January 2013
  • WO/2013/003899, Methods of treating or preventing rheumatic disease, Mesoblast, 10 January 2013
  • WO/2013/003904, Recombinant low virulence bovine herpesvirus 1 (bohv-1) vaccine vectors, Queensland Department of Agriculture, Fisheries And Forestry and Meat & Livestock Australia, 10 January 2013
  • WO/2013/003895, Combination therapy, Biosceptre International Ltd, 10 January 2013
  • WO/2013/000054, Method for producing pterocarpans, cytomodulating composition containing pterocarpans, and use of pterocarpans, Universidade Federal do Ceará, Fraunhofer-Gesellschaft and Australian National University, 3 January 2013
Copyright © 2018 NDF Research